| scholarly article | Q13442814 |
| P50 | author | Benjamin Frey | Q38326649 |
| Rainer Fietkau | Q64584867 | ||
| P2093 | author name string | Udo S Gaipl | |
| Anja Derer | |||
| Markus Hecht | |||
| Martina Spiljar | |||
| Monika Bäumler | |||
| P2860 | cites work | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 |
| The PD-1 pathway in tolerance and autoimmunity | Q24633549 | ||
| Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation | Q26744490 | ||
| Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications | Q26779221 | ||
| Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer | Q26798047 | ||
| Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers | Q27853176 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells | Q34553594 | ||
| Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy | Q35012602 | ||
| Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma | Q35176032 | ||
| IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. | Q35677893 | ||
| Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer | Q35837683 | ||
| Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner | Q36346964 | ||
| Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects | Q36778827 | ||
| At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy | Q36935749 | ||
| Immunogenicity of anthracyclines: moving towards more personalized medicine | Q37114351 | ||
| Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment | Q37268974 | ||
| Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma | Q37333645 | ||
| Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody | Q37351567 | ||
| Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors | Q37474092 | ||
| The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. | Q37799738 | ||
| Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. | Q37993183 | ||
| Immunologic and clinical effects of targeting PD-1 in lung cancer | Q38201196 | ||
| Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy | Q38217593 | ||
| Sinister self-sacrifice: the contribution of apoptosis to malignancy | Q38234939 | ||
| The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? | Q38332778 | ||
| Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors | Q38641806 | ||
| Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy | Q39707212 | ||
| Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy | Q40203106 | ||
| The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer | Q40351319 | ||
| Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor | Q40412166 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer | Q42096460 | ||
| Establishment of mouse colonic carcinoma cell lines with different metastatic properties | Q42800656 | ||
| Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade | Q50777923 | ||
| Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin | Q52145169 | ||
| Impact of localized radiotherapy on blood immune cells counts and function in humans | Q77879483 | ||
| P921 | main subject | glioblastoma | Q282142 |
| chemoradiotherapy | Q5090613 | ||
| P304 | page(s) | 610 | |
| P577 | publication date | 2016-12-22 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells | |
| P478 | volume | 7 |
| Q38679488 | A perspective on the impact of radiation therapy on the immune rheostat |
| Q96128311 | ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma |
| Q90734665 | Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma |
| Q49295345 | Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer |
| Q55093340 | Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients. |
| Q64134054 | Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma |
| Q60932213 | Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer? |
| Q61448764 | Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? |
| Q39449408 | Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma |
| Q57816055 | Durvalumab in NSCLC: latest evidence and clinical potential |
| Q100386707 | Enhancing the efficacy of immunotherapy using radiotherapy |
| Q58609492 | Harnessing the immune system in glioblastoma |
| Q52676452 | IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma |
| Q92738995 | Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence |
| Q47403025 | Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer |
| Q89884254 | Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives |
| Q33650058 | Immune Checkpoint in Glioblastoma: Promising and Challenging |
| Q92741127 | Immune biological rationales for the design of combined radio- and immunotherapies |
| Q87944374 | Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies |
| Q54970085 | Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. |
| Q48193685 | Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. |
| Q60959909 | Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend |
| Q47115510 | Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer |
| Q97543035 | Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy |
| Q92923739 | Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma |
| Q64271992 | Non-Thermal Plasma as a Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells |
| Q64075507 | Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy |
| Q47936526 | Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies |
| Q92306391 | Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy |
| Q61805065 | Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment |
| Q64987409 | PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. |
| Q90634185 | Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers |
| Q59800762 | Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade |
| Q60956725 | Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation |
| Q64279738 | Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study |
| Q64078089 | Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab |
| Q64102265 | Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors |
| Q64111589 | Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy |
| Q47140355 | Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. |
| Q92317164 | STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer |
| Q91726597 | Temozolomide promotes immune escape of GBM cells via upregulating PD-L1 |
| Q100990212 | Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer |
Search more.